A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day) compared w...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder The primary objective of the open label study is to assess long term safety and tolerability of PR OROS methylphenidate in a flexible dose regimen (18-90 mg/day) in adult subjects diagnosed with ADHD.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune